(Reuters) - Cambridge, Massachusetts-based Biogen said the drug,
lixivaptan, is an oral compound expected to enter a late-stage,
or Phase III, clinical trial this year in heart patients with
hyponatremia, a condition that occurs when the level of sodium
in the blood is too low.
Biogen will pay Philadelphia-based Cardiokine $50 million
up front and would make up to $170 million in additional
payments if and when certain development milestones were met,
as well as royalties on sales.
Read more at Reuters.com Mergers News
lixivaptan, is an oral compound expected to enter a late-stage,
or Phase III, clinical trial this year in heart patients with
hyponatremia, a condition that occurs when the level of sodium
in the blood is too low.
Biogen will pay Philadelphia-based Cardiokine $50 million
up front and would make up to $170 million in additional
payments if and when certain development milestones were met,
as well as royalties on sales.
Read more at Reuters.com Mergers News
No comments:
Post a Comment